Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231594 · ClinicalTrials.gov registry record · Phase 1
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
A Phase 1 study of Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 214
- Enrollment target
- 20
- Study locations
NCT01231594 is a Phase 1 study of Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 214 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01231594, a Phase 1 study of Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 214 participants
- Enrollment target
- 20
- Study locations
Study Summary
This rollover study is designed to provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors who have previously participated in a GlaxoSmithKline (GSK)-sponsored GSK2118436 study (parent study), who have no evidence of progressive disease and who have tolerated GSK2118436 in the parent study without significant toxicities. Subjects will be enrolled into the appropriate cohort based upon the treatment received in their parent study. Safety assessments (physical examinations, vital signs, 12-lead electrocardiograms, echocardiograms, clinical laboratory assessments, and monitoring of adverse events) will be made throughout the study. Clinical activity will be assessed using local standard of care imaging practices and the appropriate response criteria as determined by the investigator.
Conditions Studied
Interventions
- DRUG GSK2118436
- DRUG GSK1120212
- DRUG Other approved anti-cancer agent
Study Locations (20)
Arizona
- Novartis Investigative Site - Goodyear
- Novartis Investigative Site - Scottsdale
- Novartis Investigative Site - Tucson
California
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - Los Angeles
- Novartis Investigative Site - San Francisco
Tennessee
- Novartis Investigative Site - Memphis
- Novartis Investigative Site - Nashville
- Novartis Investigative Site - Nashville
Michigan
- Novartis Investigative Site - Ann Arbor
- Novartis Investigative Site - Detroit
New York
- Novartis Investigative Site - New York
- Novartis Investigative Site - New York
Pennsylvania
- Novartis Investigative Site - Philadelphia
- Novartis Investigative Site - Pittsburgh
Florida
- Novartis Investigative Site - Sarasota
New Hampshire
- Novartis Investigative Site - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2010-11-05 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01231594
The ClinicalTrials.gov registry entry for NCT01231594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which GSK2118436 is the first listed.
NCT01231594 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01231594 about?
NCT01231594 is a clinical study titled "A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors". This rollover study is designed to provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors who have previously participated in a GlaxoSmithKline (GSK)-sponsored GSK2118436 study (parent study), who have no evidence of progressive disease and who have tolerated...
What is the current status of trial NCT01231594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 214 participants. The study started on 2010-11-05. Estimated completion is 2018-04-09.
What conditions does trial NCT01231594 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01231594?
The interventions under investigation include: GSK2118436 (DRUG), GSK1120212 (DRUG), Other approved anti-cancer agent (DRUG).
Who is sponsoring clinical trial NCT01231594?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01231594 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Michigan, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.